These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 2473415

  • 1. Nigrostriatal dopamine neurons are required to maintain basal levels of substance P in the rat substantia nigra.
    Cruz CJ, Beckstead RM.
    Neuroscience; 1989; 30(2):331-8. PubMed ID: 2473415
    [Abstract] [Full Text] [Related]

  • 2. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
    Masuo Y, Pélaprat D, Montagne MN, Scherman D, Rostène W.
    Brain Res; 1990 Mar 05; 510(2):203-10. PubMed ID: 1970504
    [Abstract] [Full Text] [Related]

  • 3. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
    Lindefors N, Brodin E, Tossman U, Segovia J, Ungerstedt U.
    Exp Brain Res; 1989 Mar 05; 74(3):527-34. PubMed ID: 2468514
    [Abstract] [Full Text] [Related]

  • 4. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
    Sivam SP.
    Brain Res; 1989 Oct 23; 500(1-2):119-30. PubMed ID: 2481560
    [Abstract] [Full Text] [Related]

  • 5. Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia.
    Salin P, Hajji MD, Kerkerian-le Goff L.
    Eur J Neurosci; 1996 Aug 23; 8(8):1746-57. PubMed ID: 8921265
    [Abstract] [Full Text] [Related]

  • 6. Association of dopamine D1 and D2 receptors with specific cellular elements in the basal ganglia of the cat: the uneven topography of dopamine receptors in the striatum is determined by intrinsic striatal cells, not nigrostriatal axons.
    Beckstead RM.
    Neuroscience; 1988 Dec 23; 27(3):851-63. PubMed ID: 3150855
    [Abstract] [Full Text] [Related]

  • 7. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms.
    Reid MS, Herrera-Marschitz M, Hökfelt T, Lindefors N, Persson H, Ungerstedt U.
    Exp Brain Res; 1990 Dec 23; 82(2):293-303. PubMed ID: 1704847
    [Abstract] [Full Text] [Related]

  • 8. Localization of striatal and nigral tachykinin receptors in the rat.
    Stoessl AJ.
    Brain Res; 1994 May 16; 646(1):13-8. PubMed ID: 7519961
    [Abstract] [Full Text] [Related]

  • 9. Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons.
    Baruch P, Artaud F, Godeheu G, Barbeito L, Glowinski J, Chéramy A.
    Neuroscience; 1988 Jun 16; 25(3):889-98. PubMed ID: 2457187
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons.
    Kerkerian L, Salin P, Nieoullon A.
    Neuroscience; 1988 Sep 16; 26(3):809-17. PubMed ID: 3143926
    [Abstract] [Full Text] [Related]

  • 11. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--I. Behavioural, neurochemical and histological characterization of the lesion.
    Sirinathsinghji DJ, Heavens RP, Richards SJ, Beresford IJ, Hall MD.
    Neuroscience; 1988 Oct 16; 27(1):117-28. PubMed ID: 3264391
    [Abstract] [Full Text] [Related]

  • 12. Striatal dopamine and glutamate release: effects of intranigral injections of substance P.
    Reid MS, Herrera-Marschitz M, Kehr J, Ungerstedt U.
    Acta Physiol Scand; 1990 Dec 16; 140(4):527-37. PubMed ID: 1707211
    [Abstract] [Full Text] [Related]

  • 13. Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitro.
    Kelly E, Jenner P, Marsden CD.
    J Neurochem; 1985 Jul 16; 45(1):137-44. PubMed ID: 3923157
    [Abstract] [Full Text] [Related]

  • 14. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity.
    Reid MS, Hökfelt T, Herrera-Marschitz M, Håkanson R, Feng DM, Folkers K, Goldstein M, Ungerstedt U.
    Brain Res; 1990 Nov 05; 532(1-2):175-81. PubMed ID: 1704289
    [Abstract] [Full Text] [Related]

  • 15. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
    Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK.
    Neuroscience; 2000 Nov 05; 95(2):377-88. PubMed ID: 10658617
    [Abstract] [Full Text] [Related]

  • 16. Chronic nicotine treatment differentially regulates substance P and tyrosine hydroxylase immunoreactivity in substantia nigra ipsilateral to a unilateral lesion.
    Janson AM, Fuxe K.
    Exp Neurol; 1997 Aug 05; 146(2):575-86. PubMed ID: 9270071
    [Abstract] [Full Text] [Related]

  • 17. Activation of striatal neurons by dexamphetamine is antagonized by degeneration of striatal dopaminergic terminals.
    Warenycia MW, McKenzie GM.
    J Neural Transm; 1987 Aug 05; 70(3-4):217-32. PubMed ID: 3119772
    [Abstract] [Full Text] [Related]

  • 18. Nigrostriatal dopamine neurons receive substance P-ergic inputs in the substantia nigra: application of the immunoelectron microscopic mirror technique to fluorescent double-staining for transmitter-specific projections.
    Kawai Y, Takagi H, Kumoi Y, Shiosaka S, Tohyama M.
    Brain Res; 1987 Jan 20; 401(2):371-6. PubMed ID: 2434194
    [Abstract] [Full Text] [Related]

  • 19. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
    Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN.
    Brain Res; 1991 Jun 21; 552(1):113-8. PubMed ID: 1717109
    [Abstract] [Full Text] [Related]

  • 20. Changes in substantia nigra pars reticulata activity following lesions of the substantia nigra pars compacta.
    Sanderson P, Mavoungou R, Albe-Fessard D.
    Neurosci Lett; 1986 Jun 06; 67(1):25-30. PubMed ID: 3014391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.